Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. - sprookjes - yvandenbroek - TriplyDB

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33343445

about

Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future The development of immunoconjugates for targeted cancer therapy Theranostic applications of antibodies in oncology.The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Radioimmunotherapy of human tumours Mechanisms of action of therapeutic antibodies for cancer Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.Ibritumomab tiuxetan for non-Hodgkin's lymphoma.Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice.Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Follicular lymphoma: still Six characters in search of an author?Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.Inotuzumab ozogamicin as novel therapy in lymphomas.

P2860

Q24633710-0E6821BB-301F-4C6D-B0B3-86146508B80E Q26746934-28EA0289-74AD-486C-97F4-8A5350D37803 Q27021990-8400F8AE-F40D-48DF-843A-3E52E001904C Q27693293-AD671CED-5611-4708-B504-95235C6DDBFA Q28072397-90FC7743-CD02-4A53-8E2B-57AB7DB1F61D Q28088825-E15E3261-823F-44C7-B472-511B0C811928 Q28385366-89A2CFC4-7BAC-40B4-8AD8-DD4F8FD7199F Q29030891-0E90F0C7-48FF-4A82-92AF-700ACE260030 Q30435188-42CF1F8A-8AF2-4AB2-9751-64A59928748C Q33361773-AFFA69F4-EF3B-4E17-8522-7FC9A66A9F47 Q33369667-3DF35D1F-E924-47BB-B545-60E8AE39D654 Q33371489-3FABE4E1-1CD9-4D27-9B67-11E506362660 Q33374978-210A2897-B9B7-4CAE-96DB-8A496854F409 Q33376503-A0626259-BD9A-4FEE-9A80-C8D3F8EEDB6C Q33380518-366ABC9E-22A8-4A10-8A0C-647DFD4316DE Q33385566-F5A35541-91DE-4B59-9AC7-E06399180A1F Q33385670-CD9A9885-934E-46CD-A094-9255C9FB97EF Q33392784-00274B3C-023C-47D0-8AB4-18E150375DA6 Q33393623-A5036CCE-FCE8-4774-ABB3-729975B8F9FE Q33396522-76C50350-95E2-482C-9B09-721B507F40B4 Q33402171-4437632B-C2A6-41CA-8C43-1AE48FC01272 Q33402885-63CDA4C9-CB51-4E82-B4D0-B001A2B0683C Q33409137-1E94D5A1-8BF7-4A70-A913-949B16200FD8 Q33416554-CBB351B6-0198-4E99-8FD2-5A7A395F6FA6 Q33418199-0343F8CE-1282-4D30-A299-71284D399915 Q33425372-F77489D1-BAC9-46B8-A444-443CE55E32F1 Q33621041-309F977C-C59F-404E-8C2C-873FC9F7F14D Q33642244-F1F5345C-3F76-4E04-AB98-4A206C6E4B4E Q33645841-6C228471-B1E4-4D45-AEC9-4FC812D37B1B Q33673059-291DA355-C7F6-4C27-90AE-F4DA66FE47E6 Q33685903-1F4D4C9C-A25B-47B7-8673-61E4F807AB21 Q33690142-AE03B25E-F31D-4484-8384-9A5E2EDF1C64 Q33927978-6A6D20EE-E743-47BF-8990-307EAAF5BBB0 Q33997021-DDC00E16-E588-488C-8128-110F396F78D4 Q34255894-36DA90C1-9B23-496F-BE2B-09437E1975B5 Q34335207-C023CB47-C120-41E4-B5FF-3B08C6D85BAB Q34418442-61E7AACD-C1A6-4751-BE18-6DCF7382E7C1 Q34480345-5548610D-E3C8-46DE-9E50-A999E17102A9 Q34567445-278E9C41-D281-46FC-93AD-31A242F6C76D Q34620271-2687E716-946E-45CA-BAB5-73EAB749EC22

P2860

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33343445

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@ast

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@en

type

label

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@ast

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@en

prefLabel

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@ast

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@en

P1433

Q33343445-C86CCBB2-4894-4C2E-8F96-4F5EBE7FFC55

P1476

Q33343445-F6964DB8-154A-4733-990B-C19BD898A235

P2093

Q33343445-1758339C-8D56-4B54-BBC2-F58051DF2913

Q33343445-21029EBE-9BE2-4BB9-BCBF-0D7115AAC375

Q33343445-3657A49D-8146-4334-9D22-027014068110

Q33343445-53AAFD4B-D78F-4B49-B01B-DE10E25131B4

Q33343445-7C96CCCF-E8E5-4894-B879-91621DB99511

Q33343445-86E5FF0C-28C7-4F87-AA84-2206F735F9FC

Q33343445-B5D8EC4F-817F-4FAD-914F-1AEA0E7B43F6

Q33343445-D9B901BD-4A85-4B6F-A64A-A85DBA3DE518

Q33343445-E280B3BB-22C8-43CA-A723-D3D2C8B880B1

P304

Q33343445-DF52D061-D66A-4F07-8FAC-6D4066BECC9D

P31

Q33343445-2222D447-CCF5-4BD6-9FB1-412FFF8966F8

P356

Q33343445-039F5126-654A-4129-98E9-014BE2C2FE3D

P407

Q33343445-19E166BE-0C32-43B6-9A5D-7C8B09967E7A

P433

Q33343445-F57C94DC-7042-43CA-B7C1-E5B9B6FF4DC2

P478

Q33343445-8103BF4A-B899-4096-80EC-FA0C2C55D208

P50

Q33343445-BFD78D4F-52CA-496C-A601-CAFE08DE9540

Q33343445-F58E28D8-4AC0-4881-9E8A-C54EA101D476

P577

Q33343445-C84BF085-A9E5-4AE7-B374-308555A49435

P698

Q33343445-798FC46B-0024-4DDB-B0CE-B29F44B90B38

P356

JCO.2002.11.017

P1433

Journal of Clinical Oncology

P1476

Treatment with ibritumomab tiu ...... icular non-Hodgkin's lymphoma.

@en

P2093

Christine A White

http://www.w3.org/2001/XMLSchema#string

Christos Emmanouilides

http://www.w3.org/2001/XMLSchema#string

Gregory Wiseman

http://www.w3.org/2001/XMLSchema#string

Larry Cripe

http://www.w3.org/2001/XMLSchema#string

Mansoor N Saleh

http://www.w3.org/2001/XMLSchema#string

Myron S Czuczman

http://www.w3.org/2001/XMLSchema#string

Pratik S Multani

http://www.w3.org/2001/XMLSchema#string

Teresa Olejnik

http://www.w3.org/2001/XMLSchema#string

Thomas E Witzig

http://www.w3.org/2001/XMLSchema#string

P304

3262-3269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.11.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12149300

http://www.w3.org/2001/XMLSchema#string